Skip to main content
Biosynex logo

Biosynex — Investor Relations & Filings

Ticker · ALBIO ISIN · FR0011005933 LEI · 969500H4BGE1HBLGP566 PA Manufacturing
Open in API
Filings indexed 200 across all filing types
Latest filing 2023-03-09 Regulatory Filings
Country FR France
Listing PA ALBIO

About Biosynex

https://www.biosynex.com/en/

Biosynex is a company that specializes in the design, manufacture, and distribution of medical diagnostic solutions. Its core product line consists of Rapid Diagnostic Tests (RDTs) for both professional use in clinical settings and for self-testing by the general public. The professional portfolio includes point-of-care (POC) instruments, molecular biology diagnostics (such as PCR tests), and a wide array of immunodiagnostic assays. For the consumer market, Biosynex offers various self-tests and a range of prevention and monitoring devices, including thermometers, blood pressure monitors, and pulse oximeters. The company focuses on providing simple, rapid, and effective tools for screening, diagnosis, and prevention.

Recent filings

Filing Released Lang Actions
BIOSYNEX SA: ARRET DE LA COMMERCIALISATION DE BOUILLOTTES
Regulatory Filings Classification · 98% confidence The document announces a product recall ('rappel de bouillottes') and the subsequent withdrawal from the market ('retrait de la commercialisation') following a prefectural decree. It also mentions the financial impact (provisioning costs) and provides a date for the next major publication (Annual Results 2022). This is a specific operational/regulatory announcement concerning a product safety issue and its financial consequences, rather than a full annual report (10-K), an earnings release (ER), or a standard legal proceeding report (LTR). Since it deals with a specific regulatory action (product recall/withdrawal) and associated financial impact, it fits best under the general 'Regulatory Filings' (RNS) category as a miscellaneous regulatory announcement, as there is no specific category for product recalls. The document length is short (2682 chars), but it contains substantive information, not just an announcement of another report, thus ruling out RPA/RNS based on the 'MENU VS MEAL' rule for short documents announcing other reports. Given the nature of the announcement (product safety/regulatory action), RNS is the most appropriate fallback.
2023-03-09 French
BIOSYNEX SA: DESCRIPTIF DU PROGRAMME DE RACHAT D’ACTIONS
Transaction in Own Shares Classification · 100% confidence The document is titled "DESCRIPTIF DU PROGRAMME DE RACHAT D'ACTIONS" (Description of the Share Buyback Program). It details the authorization, objectives, modalities, and legal framework (Code de commerce, AMF regulations) for BIOSYNEX to repurchase its own shares. This content directly relates to the company's capital structure management and share transactions. The filing type that specifically covers the company buying back or selling its own shares is 'Transaction in Own Shares' (POS). Although it describes a program authorized by the AGM, the core subject is the share repurchase plan itself, not the AGM materials (AGM-R) or a general capital change announcement (SHA).
2023-02-08 French
BIOSYNEX SA: ANNONCE DES RESULTATS DEFINITIFS DE L’OPA DE BIOSYNEX SUR LES ACTIONS THERADIAG
M&A Activity Classification · 98% confidence The document is titled "ANNONCE DES RESULTATS DEFINITIFS DE L'OPA DE BIOSYNEX SUR LES ACTIONS THERADIAG" (Announcement of Final Results of the BIOSYNEX Tender Offer on THERADIAG Shares). It details the outcome of a Tender Offer (OPA) regulated by the AMF (Autorité des marchés financiers), including the number of shares tendered and the resulting ownership percentage for BIOSYNEX. This clearly relates to a corporate action involving the acquisition of shares, which falls under the scope of M&A activity or significant capital structure changes. Since the document specifically announces the final results of a takeover bid/acquisition process, the most appropriate category is M&A Activity (TAR). It is not a general financing update (CAP) or a simple share transaction report (POS), but the conclusion of a takeover process.
2023-02-01 French
BIOSYNEX SA: BIOSYNEX ET CHEMBIO DIAGNOSTICS ANNONCENT UN ACCORD DEFINITIF D’ACQUISITION
M&A Activity Classification · 99% confidence The document is a "COMMUNIQUE DE PRESSE" (Press Release) dated January 31, 2023, announcing a definitive agreement for BIOSYNEX to acquire CHEMBIO DIAGNOSTICS. This involves a tender offer (offre publique d'achat) and subsequent merger, which constitutes a significant corporate transaction related to ownership and control. Key indicators point towards M&A Activity (TAR) or Capital/Financing Update (CAP). 1. The core subject is the acquisition of one company by another ("ACCORD DEFINITIF D'ACQUISITION"). This strongly aligns with the definition of M&A Activity (TAR). 2. The text explicitly mentions the mechanics of the transaction: a tender offer, valuation ($17.2 million), and expected closing in Q1 2023. 3. Although it mentions SEC filings (Schedule TO, Schedule 14D-9), the document itself is the announcement of the deal, not the final regulatory report (10-K) or a proxy statement (DEF 14A). 4. Since the primary focus is the merger/takeover proposal, TAR (M&A Activity) is the most precise classification over CAP (which is broader financing/fundraising). 5. It is not a short announcement linking to a full report, so RPA/RNS is less appropriate than the specific M&A code.
2023-01-31 French
BIOSYNEX SA: REOUVERTURE DE L'OFFRE PUBLIQUE D'ACHAT VISANT LES ACTIONS THERADIAG
M&A Activity Classification · 98% confidence The document text is titled "REOUVERTURE DE L'OFFRE PUBLIQUE D'ACHAT, VISANT LES ACTIONS THERADIAG" (Reopening of the Public Purchase Offer targeting THERADIAG shares). It details the extension of a tender offer by BIOSYNEX for THERADIAG shares, including pricing, dates (January 18 to January 31, 2023), and ownership percentages. This clearly relates to a takeover bid or merger activity. Based on the provided definitions, the most appropriate category is 'M&A Activity' (Code: TAR), which covers merger proposals or takeover bids.
2023-01-18 French
BIOSYNEX SA: SUCCÈS DE L'OFFRE PUBLIQUE D'ACHAT INITIÉE PAR BIOSYNEX VISANT LES ACTIONS THERADIAG
M&A Activity Classification · 98% confidence The document explicitly discusses the success and reopening of a Public Acquisition Offer (Offre Publique d'Achat - OPA) initiated by BIOSYNEX for THERADIAG shares. It details the results of the offer, the resulting shareholding percentage for BIOSYNEX, and the regulatory approval/involvement of the AMF (Autorité des marchés financiers). This subject matter—a takeover bid or merger proposal—directly corresponds to the definition of M&A Activity (TAR). Although it mentions the upcoming release of annual revenue ('Chiffre d'affaires annuel 2022'), the primary focus and content of this specific document is the M&A transaction.
2023-01-16 French

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.